Differential time series analysis shows deceleration in melanoma mortality prior to the widespread use of highly effective therapies - 18/10/24
Abstract |
Background |
Although the recent drop in melanoma mortality has been attributed to the introduction of newer therapies, the impact of ongoing public efforts remains unknown.
Objective |
Characterize and model melanoma mortality trends before the era of molecular and immune therapies (1969-2014) in the U.S. and Australia.
Methods |
Differential time series analysis based on population-ascertained melanoma mortality rates from the U.S. and Australia. Mortality rates were modeled and compared to the trajectories of ten other cancers.
Results |
Melanoma mortality rates have been significantly decelerating since the 1970s in both the U.S. (P < .0001) and Australia (P = .0021). Zero acceleration occurred around 2001 (95% CI: 1996, 2008) for the U.S. and 2004 (95% CI: 1999, 2011) for Australia. Male mortality rates decelerated 3x-4x faster than females in both countries. Melanoma mortality followed a similar quadratic function (R2 > 0.9) to 10 other cancers, albeit with a later inflection point (1986 vs 2001) and broader focal width.
Limitations |
Absolute mortality data used without further stratification or considering cancer incidence or covariates.
Conclusion |
Melanoma deaths have been decelerating for the past 5 decades, reaching an inflection point around 2001, suggesting that mitigating campaigns were already afoot in both the U.S. and Australia before the advent of modern therapies.
Le texte complet de cet article est disponible en PDF.Key words : melanoma, modeling, mortality, SEER
Abbreviations used : APC, SEER, Y0
Plan
| Funding sources: This paper is supported by the Richard Allen Johnson, MD Endowed Chair in Dermatology and the generous donors to melanoma research at the Massachusetts General Hospital (to H.T.). |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable. |
|
| Data sharing statement: All data are publicly available via the National Center for Health Statistics' (NCHS) National Vital Statistics System (NVSS) (United States), and National Cancer Control Indicators (Australia). All data used to generate the figures are included in the Supplementary Tables, available via Mendeley at 1. |
Vol 91 - N° 5
P. 872-879 - novembre 2024 Retour au numéro
Article précédent
- JAAD Game Changers: Azathioprine treatment of intractable pruritus: A retrospective review
- Jane M. Grant-Kels
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Brett King, Maryanne M. Senna, Natasha A. Mesinkovska, Charles Lynde, Matthew Zirwas, Catherine Maari, Vimal H. Prajapati, Sheetal Sapra, Pawel Brzewski, Lawrence Osman, Sameh Hanna, Marni C. Wiseman, Colleen Hamilton, James Cassella
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?